Based on interrogation of public coronavirus data, Asymmetrex Director Sherley reports suspicion of a misread on COVID-19 spread In a preprint posted on medRxiv, Asymmetrex Director James Sherley reports the discovery of surprising relationships between how many positive coronavirus tests are found and how many tests were given. Everyone recognizes that if no tests were
SuperbCrew, a business news website dedicated to covering innovative companies in the tech and business fields, recently interviewed Asymmetrex CEO James L. Sherley. Dr. Sherley discusses Asymmetrex’s background, his personal background, and the newly developed algorithms for rapid low cost counting of therapeutic tissue stem cells. “Together AlphaSTAR and Asymmetrex solve the 6 decades unsolved
Today, at the 6th Annual Perinatal Stem Cell Society Congress in Salt Lake City, Utah, Massachusetts stem cell biotechnology company Asymmetrex will announce its newest advance in technologies for specific counting of tissue stem cells. The company will report the use of its AlphaSTEM Test™ technology to discover the first mathematical algorithms for rapidly calculating
RegMedNet highlighted Asymmetrex and its Counting Stem Cells podcast from James Sherley, founder and director of Asymmetrex. The Counting Stem Cells podcast has six episodes outlining current usage of stem cells, the current counting problem, why it matters, the Asymmetrex solution, and a vision for the future. “We cannot continue to work in the field
Online news platform Tech Company News caught up with Asymmetrex Director James Sherley to ask him about his expectations for Asymmetrex’s new membership in ARMI. “Working with our partner AlphaSTAR Corporation, Asymmetrex has solved the first problem. We now offer the first ever technology for specific and accurate counting of any human tissue stem cell type, including
Recently, Asymmetrex LLC joined forces with a new public-private Manufacturing USA Initiative, the Advanced Regenerative Manufacturing Institute (ARMI). ARMI highlighted Asymmetrex in its New Member Spotlight. This member spotlight goes into detail about the crucial hurdle regenerative medicine is currently facing — a quantitative discipline for tissue stem cells. Dr. James Sherley speaks to ARMI
The Advanced Regenerative Manufacturing Institute (ARMI) will receive more than $300 million in public-private investment from leading manufacturers, universities, nonprofit organizations and the federal government to develop scalable manufacturing processes for engineered tissues and organs. Asymmetrex LLC is part of a new public-private Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (ARMI). Headquartered in Manchester,
Asymmetrex Founder and Director James L. Sherly, M.D., Ph.D. recently wrote an article for The Scientist magazine that addresses the ethics around the peer-review of academic manuscripts submitted for publication in research journals. “Whether co-reviewers are named or not, this practice, along with the more patently unethical ghostwriting, has no defensible place in the live
Director James Sherley M.D., Ph.D. visits COAACH at North Carolina A&T State University to talk with future biotech entrepreneurs about the principles of biotechnology commercialization illustrated with the origin story of Asymmetrex. Listen to the talk here.
Massachusetts stem cell biotechnology company Asymmetrex began sponsorship of a new informational podcast in October of this year. Titled “Counting Stem Cells For A New Era Of Medicine,” the educational podcast explains and amplifies the FDA’s recent attention to a long-standing, significant deficiency in stem cell medical practice, giving patients stem cell treatments without knowing